Skip to main content
SpringerLink
Log in

Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer

  • Chapter
Thoracic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 105))

  • 107 Accesses

Abstract

It is estimated that approximately 164,000 cases of lung cancer will occur in 2000 (1) with 84% of the patients (138,000 individuals) having non-small cell lung cancer. (NSCLC) (2). The number of deaths due to non-small cell lung is virtually equal to the combined total deaths of breast cancer, prostate cancer, and colon cancer, which are the second, third, and fourth leading causes of deaths in the United States (1). A large percentage, approximately 44%, of non-small cell lung cancer patients will have locally advanced disease (stage IIIa/b) (3). Previously, radiation therapy has been the sole treatment modality for this group ofpatients. Although this treatment provides palliation of dyspnea, cough, hemoptysis, pain, and other symptoms from locally advanced disease, the overall five year survival is approximately 5% (4-6). The disappointing long term survival in stage III NSCLC is due to both recurrent local regional disease and to the development of distant metastases. The results of efforts to develop more effective local treatment are discussed in chapter, while studies in which chest radiation was combined with systemic therapy are reviewed here.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Society. Cancer Facts and Figures 2000: Pages 11–12.

    Google Scholar 

  2. Travis WD, Travis LB, Devessa SS. Lung Cancer. Cancer 75:191–202, 1995.

    Article  PubMed  CAS  Google Scholar 

  3. Bulzebruck H, Bopp R, Drings P, et al. New aspects of the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70: 1102–1110, 1992.

    Article  PubMed  CAS  Google Scholar 

  4. Dillman RP, Herndon J, Seagren SL, et al. Improved survival in stage III NSCLC: Seven year follow-up of CALGB 8433. J Natl Cancer Inst 88:12101215, 1996.

    Google Scholar 

  5. Arriagada R, LeChevalier et al. Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): late analysis of the French randomized trial. Proc Am Soc Clin Oncol 16:446a (abstr 1601), 1997.

    Google Scholar 

  6. Sause WT, Kolesar P, Taylor SG et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 17 (2): 212–223, 2000.

    Google Scholar 

  7. Bonomi P. Brief overview of combination chemotherapy in non-small cell lung cancer. Semin Oncol 13(suppl 3): 89–9, 1986.

    PubMed  CAS  Google Scholar 

  8. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med J 311: 899–909, 1995.

    Article  Google Scholar 

  9. Marino P, Preatoni A, Cantoni A. Randomized trials for radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. Cancer 76:593–60, 1995.

    Article  PubMed  CAS  Google Scholar 

  10. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. Ann Intern Med 125:723–729, 1996.

    PubMed  CAS  Google Scholar 

  11. Dillman R, Seagren SL, Propert K, et al. A randomized trial of induction chemotherapy plus high-dose radiatin versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940–945, 1990.

    Article  PubMed  CAS  Google Scholar 

  12. Sause WT, Scott C, Taylor S, et al. RTOG 8808 and ECOG 4588. Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer. J Natl Cancer Inst 87:198–205, 1995.

    Article  PubMed  CAS  Google Scholar 

  13. LeChevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analyses of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–422, 1991

    Article  CAS  Google Scholar 

  14. Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477–482, 1988.

    Article  PubMed  CAS  Google Scholar 

  15. Morton RF, Jett JR, McGinnis WL, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally advanced unresectable non-small cell lung cancer. A randomized phase III trial. Ann Intern Med 1151:681–686, 1991.

    Google Scholar 

  16. Crino L, Latini P, Meacci M, et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small cell lung cancer. Ann Oncol 4:847–851, 1993.

    PubMed  CAS  Google Scholar 

  17. Schaake-Koning C, Vanden Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524–530, 1992.

    Article  PubMed  CAS  Google Scholar 

  18. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer: Int J Rad Oncol Biol Phys 24(1):11–15, 1992.

    Article  CAS  Google Scholar 

  19. Soresi E, Clerici M et al. A randomized clinical trial comparing radiation therapy, radiation therapy plus cis-Dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Sem Oncol 15(6) (Suppl 7): 20–25, 1988.

    CAS  Google Scholar 

  20. Bishop JF, Ball DL, Smith JG, et al. A randomized phase III trial of concurrent carboplatin and twice daily radiotherapy (RT) in locally advanced non-small cell lung cancer. (NSCLC). Proc Am Soc Clin Oncol 17:464a, 1998.

    Google Scholar 

  21. Groen HJM, VanderLeest AHW, Snoek WJ, et al. Phase III study of continuous carboplatin over 6 weeks with radiation versus radiation alone in stage III on-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18:466a (abstr 1797), 1999.

    Google Scholar 

  22. Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 11:1391–1402, 1993.

    PubMed  CAS  Google Scholar 

  23. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 12:2682–2686, 1994.

    PubMed  CAS  Google Scholar 

  24. Choy H, Safran H, Akerley W, et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Can Res 4:1931–1936, 1998.

    CAS  Google Scholar 

  25. Lau D, Ryu J, Grandara D. Concurrent twice—weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Seminar Radiat Oncol 9 (2 Suppl 1):117–120, 1999.

    CAS  Google Scholar 

  26. Amdal S, Wibe E, Hallen M, et al. Phase I study of concomitant docetaxel (Taxotere) and radiation in locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16:460a, 1997.

    Google Scholar 

  27. Teng M. Choy H, DeVore KR, et al. Phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non-small cell lung cancer: A Vanderbilt Cancer Center affiliate network (VCCAN). Proc Am Soc Clin Oncol 17:503a, 1998.

    Google Scholar 

  28. Koukourakis M, Bahlitzanakis N, Froudarakis M, et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small cell lung cancer. British Journal of Cancer 80 (11): 1792–1796, 1999.

    Google Scholar 

  29. Scalliet P, Goor C, Galdermans D, et al. Gemzar (gemcitabine) with thoracic radiotherapy — a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:499a, 1998.

    Google Scholar 

  30. Zinner RG, Fossella FV, Komaki R, et al. Gemcitabine with concurrent 3D conformal radiation followed by consolidation gemcitabine plus cisplatin: a phase I trial for patients with stage III non-small cell lung cancer. Proc Amer Soc Clin Oncol 19:510a, 2000.

    Google Scholar 

  31. Kudoh S, Kuriharan, Akishio K, et al. A phase I-II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15: 372, 1996.

    Google Scholar 

  32. Saka H, Shimokata K, Yoshida S, Shimokata K, Yoshida S, et al. Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): a phase II study of Japan Clinical Oncology Group (JCOG 9504). Proc Am Soc Clin Oncol 16: 447a, 1997.

    Google Scholar 

  33. Edelstein MP., Wolfe LA, Duch DS. Potentiation of radiation radiation therapy by vinorelbine (navelbine) in non-small cell lung cancer. Semin Oncol 23 (Suppl 5): 41–47, 1996.

    PubMed  CAS  Google Scholar 

  34. Jeremic B, Shabamoto Y, Acimovic L. et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 13:452–458, 1995.

    PubMed  CAS  Google Scholar 

  35. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin etoposide for stage III non-small cell lung cancer: A randomized study. J Clin Oncol 14 (14): 1065–1070, 1996.

    PubMed  CAS  Google Scholar 

  36. Choy H, Akerley W, Safran H, et al. Multi-institutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol 16 (10): 3316–3322, 1998.

    PubMed  CAS  Google Scholar 

  37. Belani CP., Aisner J, Day R. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): three year follow-up. Proc Am Soc Clin Oncol 16:448a (abstr 1608), 1997.

    Google Scholar 

  38. Choy H, DeVore RD, Hande JR, et al. Phase II study of paclitaxel, carboplatin and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. A Vanderbilt cancer center affiliate network (VCCAN) trial (Proc Am Soc Clin Oncol 17:467a (abstr 1794), 1998.

    Google Scholar 

  39. Lau D, Leigh B, Gandova DR, et al. Weekly carboplatin twice weekly, paclitaxel, and thoracic radiation followed by carboplatin/paclitaxel for stage III non-small cell lung cancer. Semin Oncol 26 (suppl 2): 70, 1999.

    Google Scholar 

  40. Masters GA, Havat DJ, Hoffman PC, et al. Phase I study of vinorelbine, cisplatin and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16: 2157–2163, 1998.

    PubMed  CAS  Google Scholar 

  41. Zatloukal P, Petruzelka L, Zowanova M, et al. Vinorelbine (VRL) plus cuisplatin (CODP) and concurrent radiotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:505a, 1998.

    Google Scholar 

  42. Fukuda M, Soda H, Ichiki M, et al. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) in locally advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 18: 466a, 1999.

    Google Scholar 

  43. Yokoyama A, Kurita Y, Saijo N, et al. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small cell lung cancer. Br. J Cancer 78(2): 257–262, 1998.

    Article  PubMed  CAS  Google Scholar 

  44. Blanke C, Ansari R, Mantravadi R, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 13:1425–1429, 1995.

    PubMed  CAS  Google Scholar 

  45. Furuse K, Fukuoka M, Kowahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17:2692–2699, 1999.

    PubMed  CAS  Google Scholar 

  46. Curran WJ Jr, Scott C, Langer C, et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: initial report of radiation therapy oncology group (RTOG) 9410. Proc Amer Soc Clin Oncol 19:484a, 2000.

    Google Scholar 

  47. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4–11, 1999.

    PubMed  CAS  Google Scholar 

  48. Vokes E, Leopold KA, Herndori JE, et al. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer. (CCALGB study 9431). Proc Amer Soc Clin Oncol 18:459a, 1999.

    Google Scholar 

  49. LeChevalier T, Brisgand D, Douillard J, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin and vindesine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 360–367, 1994.

    CAS  Google Scholar 

  50. Sandler AB, Nemunaitis J, Denhem C, et al. Phase III trial of gemicitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18:122–130, 2000.

    PubMed  CAS  Google Scholar 

  51. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin results of Eastern Cooperative group trial. J Clin Oncol 18:623–631, 2000.

    PubMed  CAS  Google Scholar 

  52. Zhu Z, Witte L, Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 17:195–212, 1999.

    Article  PubMed  CAS  Google Scholar 

  53. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 17:2941–2953, 1999.

    PubMed  CAS  Google Scholar 

  54. Rowinsky EK, Winoele JJ, Von Hoff DD. Ras protein farnesy/transferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17:3631–3652, 1999.

    Google Scholar 

  55. Levitt ML, Koty PP. Tyrosine Kimase inhibitors in preclinical development. Inves New Drugs 17:215–226, 1999.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rush Medical Center, Chicago, IL, 60612, USA

    Philip Bonomi MD & Wasif Shirazi MD

Authors
  1. Philip Bonomi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wasif Shirazi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland, USA

    David S. Ettinger MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bonomi, P., Shirazi, W. (2001). Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer. In: Ettinger, D.S. (eds) Thoracic Oncology. Cancer Treatment and Research, vol 105. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1589-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1589-0_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5629-5

  • Online ISBN: 978-1-4615-1589-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation